Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.46 |
| ▸ | ADAM17 | P78536 | 10/20 | 0.45 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.44 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.42 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | MMP14 | P50281 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9288425 | 1.00 | RIPK1 (0.46) | RIPK1ADAM17TRPC3TRPC6EPHX2 | |
| SCHEMBL9289717 | 0.87 | ADAM17 (0.45) | ADAM17NPC1 | |
| SCHEMBL859434 | 0.87 | RIPK1 (0.44) | RIPK1ADAM17EPHX2ADAM10MMP1 | |
| SCHEMBL840107 | 0.87 | RIPK1 (0.44) | RIPK1ADAM17EPHX2ADAM10MMP1 | |
| SCHEMBL840108 | 0.87 | RIPK1 (0.44) | RIPK1ADAM17EPHX2ADAM10MMP1 | |
| SCHEMBL9288463 | 0.79 | RIPK1 (0.54) | RIPK1ADAM17TRPC3TRPC6EPHX2 | |
| SCHEMBL9289726 | 0.78 | RIPK1 (0.53) | RIPK1ADAM17TRPC3TRPC6EPHX2 | |
| SCHEMBL9288767 | 0.75 | RIPK1 (0.52) | RIPK1ADAM17TRPC3TRPC6EPHX2 | |
| SCHEMBL840832 | 0.75 | ADAM17 (0.45) | ADAM17 | |
| SCHEMBL9285815 | 0.73 | SMN1; SMN2 (0.56) | NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324217-B2 | Cold menthol receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2012-12-04 | — | — | US | disclosed |
| US-20120136006-A1 | COLD MENTHOL RECEPTOR ANTAGONISTS | COLBURN RAYMOND W (US) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136006-A1 | COLD MENTHOL RECEPTOR ANTAGONISTS | TRPV1, TRPM2, TRPM6 | RIPK1 3006/4885ADAM17 4368/4885TRPC3 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.